Clinical evidences of urea at high concentration on skin and annexes.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
29
03
2020
revised:
06
08
2020
accepted:
23
09
2020
entrez:
29
11
2020
pubmed:
30
11
2020
medline:
28
4
2021
Statut:
ppublish
Résumé
The antiproliferative, keratolytic, moisturizing and emollient properties of urea are already known. Clinical evidences of urea at high concentration indicate its important role in the presence of hyperkeratosis that, if severe or localized in specific body areas, may cause discomfort to the patient and may interfere with absorption of topical drugs, delaying response to treatment. Other important uses of urea at high concentration are on the scalp and on nail plate. The keratolytic effect of urea is well-tolerated and virtually free from side effects. Compliance with topical therapy is directly related to the aesthetic and sensory acceptability of a topical agent that may considerably vary in odour, spreadability and post-application residue.
Substances chimiques
Keratolytic Agents
0
Urea
8W8T17847W
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13740Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Loden M, Andersson AC, Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol. 1999;140:264-267.
IMS monthly national prescription audit, MAT Oct 2004 through Oct 2006. Plymouth Meeting (PA): IMS Health; 2006.
van Zuuren EJ, Fedorowicz Z, Arents BWM. Emollients and moisturisers for eczema: abridged Cochrane systematic review including GRADE assessments. Cochrane Database Syst Rev. 2017;2:CD012119.
Loden M. Urea-containing moisturizers influence barrier properties of normal skin. Arch Dermatol Res. 1996;288:103-107.
Loden M. Barrier recovery and influence of irritant stimuli in skin treated with a moisturizing cream. Contact Dermatitis. 1997;36:256-260.
Treffel P, Gabard B. Stratum corneum dynamic function measurements after moisturizer or irritant application. Arch Dermatol Res. 1995;287:474-479.
Bettinger J, Gloor M, Gehring W, Wolf W. Influence of emulsions with and without urea an water-binding capacity of the stratum corneum. J Soc Cosmet Chem. 1995;46:247-254.
Muller KH, Pflugshaupt C. Urea in dermatology I. Hautarzt. 1989;40(Suppl 9):1-12.
Wohlrab W, Schiemann S. Investigations on the mechanism of the activity of urea upon the epidermis (author’s transl). Arch Dermatol Res. 1976;255:23-30.
Wohlrab W. Harnstoff-ein bewährter Wirkstoff in der Dermatologie und Kosmetik. P Z. 1992;33:9-15.
Fluhr JW, Cavallotti C, Berardesca E. Emollients, moisturizers, and keratolytic agents in psoriasis. Clin Dermatol. 2008;26:380-386.
Philipp S, Wolk K, Kreutzer S, et al. The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorder. Expert Opin Ther Targets. 2006;10:817-831.
Bikowski J. The use of therapeutic moisturizers in various dermatologic disorders. Cutis. 2001;68:3-11.
Schopf E, Mueller JM, Ostermann T. Value of adjuvant basic therapy in chronic recurrent skin diseases. Neurodermatitis atopica/psoriasis vulgaris. Hautarzt. 1995;46:451-454.
Micali G, Luca M, Verzì AE, Musumeci ML, Lacarrubba F. Ultrasound assessment of the keratolytic effect of a 50% urea anhydrous paste on psoriasis plaque: a prospective study. G Ital Dermatol Venereol. 2019;154:509-512.
Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H. Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol. 2000;39:532-534.
Piraccini BM, Starace M, Toft A. Early visible improvements during K101-03 treatment: an open-label multicenter clinical investigation in patients with onychomycosis and/or nail psoriasis. Dermatology. 2017;233:178-183.
Piraccini BM, Bruni F, Alessandrini A, Starace M. Evaluation of efficacy and tolerability of four weeks bifonazole treatment after nail ablation with 40% urea in mild to moderate distal subungual onychomycosis. G Ital Dermatol Venereol. 2016;151:32-36.
Markeeva E, Hinterberger L, Vogt T, Rass K. Combined surgical treatment of a pincer nail with chemical matricectomy, median nail incision, and splinting. J Dtsch Dermatol Ges. 2015;13:256-259.
Feldman SR, Housman TS. Patients’ vehicle preference for corticosteroid treatments of scalp psoriasis. Am J Clin Dermatol. 2003;4:221-224.
Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39:S67-S73.
Ademola J, Frazier C, Kim SJ, Theaux C, Saudez X. Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. Am J Clin Dermatol. 2002;3:217-222.
Alvim Sant’Anna Addor F, Schalka S, Melo Cardoso Pereira V, et al. The skin moisturizing effects of different concentrations of urea: a clinical and corneometry study. Surg Cosmetic Dermatol. 2009;1:5-9.
Piraccini BM, Alessandrini A, Bruni F, Starace M. Acute periungueal dermatitis induced by application of urea-containing cream under occlusion. J Dermatol Case Rep. 2012;1:18-22.